Effects of the PCSK9 C378W Mutation on PCSK9 Levels and Lipid Profiles in Taiwanese Individuals: A Loss-of-Function Mutation with Potential Cardiovascular Benefits

<b>Background</b>: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of lipid metabolism. The rare PCSK9 C378W (rs776752113) mutation influences the level of low-density lipoprotein cholesterol (LDL-C); however, its association with PCSK9 levels remain unclear. <b>Methods</b>: This study investigates the frequency of the C378W mutation and its effects on PCSK9 levels and lipid profiles in 5901 Taiwan Biobank participants, including 1486 individuals with available whole-genome sequencing data. The C378W mutations were detected using a TaqMan genotyping assay and confirmed using direct DNA sequencing. <b>Results</b>: Whole-genome sequencing data revealed a single carrier of the C378W mutation. The TaqMan assay identified seven carriers of the 378W allele (7/5901 [0.119%]). After the exclusion of an individual with a history of hyperlipidemia, six carriers exhibited significantly lower levels of LDL-C (-30.5%) and PCSK9 (-56.4%) than noncarriers (LDL-C: 81.17 ± 21.79 vs. 116.70 ± 30.70 mg/dL [<i>p</i> = 0.0005]; PCSK9: 67.20 ± 14.83 vs. 154.02 ± 45.52 ng/mL [<i>p</i> = 3.59 × 10<sup>-12</sup>]. Moreover, carriers exhibited significantly lower levels of total cholesterol (-18.6%) and non-high-density lipoprotein cholesterol (non-HDL-C; -28.4%) than noncarriers (total cholesterol: 157.17 ± 19.30 vs. 193.18 ± 35.22 mg/dL [<i>p</i> = 0.0035]; non-HDL-C: 99.50 ± 20.22 vs. 138.91 ± 34.97 mg/dL [<i>p</i> = 0.0005]). Mediation analysis suggests that the association between the C378W mutation and LDL-C levels persisted even after adjustment for PCSK9 levels. Functional characterization indicates that the C378W mutation impairs protein stability and function. <b>Conclusion</b>: In conclusion, the rare C378W mutation represents a loss-of-function mutation in the Taiwanese population. This variant is independently associated with reduced PCSK9 levels and improved lipid profiles, highlighting its potential cardioprotective role.

Authors

Institutions

Publication Details

Journal
Genes
Published
2025-09-19
DOI
https://doi.org/10.3390/genes16091113
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effects of the PCSK9 C378W Mutation on PCSK9 Levels and Lipid Profiles in Taiwanese Individuals: A Loss-of-Function Mutation with Potential Cardiovascular Benefits

Yu‐Lin Ko, Lung‐An Hsu, Kun‐Huei Yeh, Semon Wu
Genes
Lipoproteins and Cardiovascular Health
article

Effects of the PCSK9 C378W Mutation on PCSK9 Levels and Lipid Profiles in Taiwanese Individuals: A Loss-of-Function Mutation with Potential Cardiovascular Benefits

Yu‐Lin Ko, Lung‐An Hsu, Kun‐Huei Yeh, Semon Wu
article en

Abstract

<b>Background</b>: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of lipid metabolism. The rare PCSK9 C378W (rs776752113) mutation influences the level of low-density lipoprotein cholesterol (LDL-C); however, its association with PCSK9 levels remain unclear. <b>Methods</b>: This study investigates the frequency of the C378W mutation and its effects on PCSK9 levels and lipid profiles in 5901 Taiwan Biobank participants, including 1486 individuals with available whole-genome sequencing data. The C378W mutations were detected using a TaqMan genotyping assay and confirmed using direct DNA sequencing. <b>Results</b>: Whole-genome sequencing data revealed a single carrier of the C378W mutation. The TaqMan assay identified seven carriers of the 378W allele (7/5901 [0.119%]). After the exclusion of an individual with a history of hyperlipidemia, six carriers exhibited significantly lower levels of LDL-C (-30.5%) and PCSK9 (-56.4%) than noncarriers (LDL-C: 81.17 ± 21.79 vs. 116.70 ± 30.70 mg/dL [<i>p</i> = 0.0005]; PCSK9: 67.20 ± 14.83 vs. 154.02 ± 45.52 ng/mL [<i>p</i> = 3.59 × 10<sup>-12</sup>]. Moreover, carriers exhibited significantly lower levels of total cholesterol (-18.6%) and non-high-density lipoprotein cholesterol (non-HDL-C; -28.4%) than noncarriers (total cholesterol: 157.17 ± 19.30 vs. 193.18 ± 35.22 mg/dL [<i>p</i> = 0.0035]; non-HDL-C: 99.50 ± 20.22 vs. 138.91 ± 34.97 mg/dL [<i>p</i> = 0.0005]). Mediation analysis suggests that the association between the C378W mutation and LDL-C levels persisted even after adjustment for PCSK9 levels. Functional characterization indicates that the C378W mutation impairs protein stability and function. <b>Conclusion</b>: In conclusion, the rare C378W mutation represents a loss-of-function mutation in the Taiwanese population. This variant is independently associated with reduced PCSK9 levels and improved lipid profiles, highlighting its potential cardioprotective role.

GenesVol. 16(9)
Chang Gung University (TW), Tzu Chi University (TW), Chinese Culture University (TW), Chang Gung Memorial Hospital (TW), Taoyuan Chang Gung Memorial Hospital (TW), Taipei Tzu Chi Hospital (TW)
Openalex Percentile: Top 59%
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.